{"id":"bopv-ipv-6-14-weeks","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The bOPV/IPV vaccine contains inactivated poliovirus and Haemophilus influenzae type b antigens. Upon administration, the antigens stimulate the body's immune system to produce antibodies that provide immunity against poliovirus and Haemophilus influenzae type b infections.","oneSentence":"bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:38.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against poliovirus and Haemophilus influenzae type b infections"}]},"trialDetails":[{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT05677256","phase":"PHASE4","title":"A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2023-11-09","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT06114810","phase":"PHASE4","title":"Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-11","conditions":"Polio","enrollment":880},{"nctId":"NCT03722004","phase":"PHASE4","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-12-18","conditions":"Poliomyelitis","enrollment":1256},{"nctId":"NCT03202719","phase":"PHASE4","title":"Duration of IPV Priming and Antibody Decay","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-11-05","conditions":"Poliomyelitis","enrollment":1645},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT02477046","phase":"PHASE3","title":"Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2015-04","conditions":"Vaccine Virus Shedding","enrollment":810},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT02189811","phase":"PHASE4","title":"Polio End-game Strategies - Poliovirus Type 2 Challenge Study","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-09","conditions":"Poliomyelitis","enrollment":900},{"nctId":"NCT02291263","phase":"PHASE3","title":"Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"Poliomyelitis","enrollment":738},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01813604","phase":"PHASE3","title":"Immunogenicity of Inactivated and Live Polio Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-11","conditions":"Poliomyelitis","enrollment":1206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bOPV/IPV (6 & 14 weeks)","genericName":"bOPV/IPV (6 & 14 weeks)","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b. Used for Protection against poliovirus and Haemophilus influenzae type b infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}